Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Amarna and NorthX signature Henk Streefkerk (CEO Amarna Therapeutics) and Janet Hoogstraate (CEO NorthX Biologics) after ...

RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.

Detailed price information for Klotho Neurosciences Inc (KLTO-Q) from The Globe and Mail including charting and trades.

Cellular Origins, the Cell and Gene Therapy Catapult, and Resolution Therapeutics have formed a consortium funded by Innovate ...

University of Osaka researchers used genome editing to program mouse liver cells to produce exenatide, a weight-loss drug.

AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s Yokohama Technical Center.